Abnormal uterine bleeding

PRISM MarketView Launches Emerging Women’s Health Index

Retrieved on: 
Thursday, January 4, 2024
Aspira, Health, Boston Consulting Group, Ovarian cancer, Regeneration, Therapy, AbbVie, Abnormal uterine bleeding, Artificial intelligence, PRISM, Growth, Birth, AUB

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Women’s Health Index. The growth of the women’s health market is accelerating with the introduction of next-generation therapeutics and artificial intelligence (AI) powered imaging and diagnostics tools. The PRISM index tracks emerging companies delivering innovative solutions to address women’s health issues.

Key Points: 
  • NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Women’s Health Index .
  • The PRISM index tracks emerging companies delivering innovative solutions to address women’s health issues.
  • PRISM Emerging Women’s Health Index outperformers this week include Minerva Surgical , which is up 12.63% in morning trading on Thursday, Sera Prognostics which has risen 6.90% and Agile Therapeutics which has gained 1.84%
    PRISM MarketView reviewed a selection of the companies set to transform the women’s health landscape in 2024.
  • Aspira Women's Health is dedicated to transforming women's health, starting with ovarian cancer.

Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 8, 2023
UTRS, Minerva Surgical, Inc. v. Hologic, Inc., AUB, Abnormal uterine bleeding, Holocene, Telephone, Online shopping

SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023.

Key Points: 
  • SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com .
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

Minerva Surgical Closes $30 Million Private Placement of Common Stock

Retrieved on: 
Thursday, February 9, 2023
Abnormal uterine bleeding, Security (finance), AUB, Sale, New Enterprise Associates, Growth, Woman, Research, Medical device

Gross proceeds of the private placement are approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical.

Key Points: 
  • Gross proceeds of the private placement are approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical.
  • Piper Sandler acted as sole placement agent for the private placement.
  • Minerva Surgical intends to use the net proceeds from the private placement, together with existing cash and cash equivalents, to support operations, research and development activities, working capital and other general corporate purposes.
  • Minerva Surgical has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock issued in this private placement.

Uterinekind Launches U by Uterinekind, An Educational Platform Helping Transform Uterine Healthcare from the Palm of Your Hands

Retrieved on: 
Wednesday, January 18, 2023
Cornell University, Associate, Shared decision-making in medicine, Education, Polycystic ovary syndrome, Nutritional science, Hand, Laboratory, Female, Health, BIPOC, PCOS, Diagnosis, Abnormal uterine bleeding, Patient, Metabolism, Uterus, Uterine prolapse, Research, Health literacy, Pelvic inflammatory disease, Doctor of Philosophy, Multimedia, Physician, Birth control, Health insurance, Medical device, Fibroid, Endometriosis

BOSTON, Jan. 18, 2023 /PRNewswire/ -- On average, at least one in ten people born with a uterus will suffer from one or more debilitating chronic conditions that primarily impacts the female body, such as Endometriosis, Fibroids, Polycystic Ovarian Syndrome (PCOS), and chronic pelvic pain. These conditions remain understudied, underdiagnosed, and under researched. The need for more resources and support is imperative for patients, and now there is a new way for them to get in control of their uterine health. Introducing U by Uterinekind, a one-of-a-kind platform putting patients in the driver's seat of their care by helping create more self-awareness and education about common gynecologic conditions.

Key Points: 
  • Introducing U by Uterinekind , a one-of-a-kind platform putting patients in the driver's seat of their care by helping create more self-awareness and education about common gynecologic conditions.
  • U by Uterinekind provides its members with everything they need to navigate their path through diagnosis, treatment, and recovery.
  • The app focuses on chronic conditions such as Endometriosis, PCOS, Abnormal Uterine Bleeding, Pelvic Inflammatory Disease, Uterine Prolapse and Chronic Pelvic Pain.
  • U by Uterinekind aims to improve uterine care for everyone by helping those dealing with uterine conditions connect the dots on their symptoms.

Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Abnormal uterine bleeding, Conference, AUB, Medical device

SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time.

Key Points: 
  • SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time.

Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

Retrieved on: 
Wednesday, December 28, 2022
Abnormal uterine bleeding, Sports medicine, Isenberg School of Management, University of Massachusetts, Smith, BS, Employment, Retirement, Growth, AI, Boston Scientific, Marketing, University, FDA, AUB, Senior, Woman, Management

The Company’s board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023.

Key Points: 
  • The Company’s board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023.
  • Todd’s experience leading best-in-class medical device companies and driving market growth is a great strategic fit for the Company.
  • Minerva Surgical is in a great operational position and is led by an experienced management team.
  • Mr. Usen holds a BS in Marketing from the Isenberg School at the University of Massachusetts.

Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners

Retrieved on: 
Tuesday, December 27, 2022
Abnormal uterine bleeding, Research, Security (finance), Growth, New Enterprise Associates, AUB, Sale, Woman

Gross proceeds of the private placement are expected to be approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical.

Key Points: 
  • Gross proceeds of the private placement are expected to be approximately $30 million, before deducting placement agent fees and other expenses payable by Minerva Surgical.
  • The private placement is expected to close in the first quarter of 2023 subject to the satisfaction of customary closing conditions and approval of the private placement by the Minerva Surgical stockholders.
  • With the proceeds from the private placement, Minerva Surgical expects to extend its cash runway for at least the next 12 months.
  • Minerva Surgical has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock to be issued in this private placement.

Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Hysterectomy, Abnormal uterine bleeding, Woman, Uterus, AUB, Conference, Minerva, Medical device

SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY.

Key Points: 
  • SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 11:00 a.m. Eastern Time in New York City, NY.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
  • The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies.
  • The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

Minerva Surgical Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Marketing, COVID-19, Adjustment, Abnormal uterine bleeding, EBITDA, Uterus, AUB, PPP, Telephone, Hospital, Projection, Government, Genesys, Hysterectomy, Risk, Depreciation, Woman, Medical device, Video game, Pharmaceutical industry, Aquaculture, Bookkeeping

SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022.

Key Points: 
  • SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported third quarter financial results for the period ended September 30, 2022.
  • Overall gross margin was 54.1% for the third quarter of 2022, decreasing from the gross margin of 57.0% in the same period of 2021 and 59.0% reported in the second quarter of 2022.
  • Adjusted EBITDA for the third quarter of 2022 was negative $5.8 million, compared to negative $2.6 million for the same period in 2021, and negative $4.5 million in the second quarter of 2022.
  • Minerva Surgical will host a conference call to discuss the third quarter 2022 financial results after market close on Monday, November 14, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Monday, November 7, 2022
Nasdaq, GLOBE, Telephone, Hysterectomy, Woman, Minerva, Uterus, Abnormal uterine bleeding, AUB, Company, Holocene, Medical device

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.

Key Points: 
  • SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has changed the date of its previously announced earnings conference call.
  • It will now report its third quarter 2022 financial results on Monday, November 14, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.